230 related articles for article (PubMed ID: 23977965)
41. Evaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil.
Storti-Melo LM; Souza-Neiras WC; Cassiano GC; Taveira LC; Cordeiro AJ; Couto VS; Póvoa MM; Cunha MG; Echeverry DM; Rossit AR; Arévalo-Herrera M; Herrera S; Machado RL
Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):58-63. PubMed ID: 21292879
[TBL] [Abstract][Full Text] [Related]
42. Antibody Responses to
McLean ARD; Boel M; McGready R; Ataide R; Drew D; Tsuboi T; Beeson JG; Nosten F; Simpson JA; Fowkes FJI
Am J Trop Med Hyg; 2017 May; 96(5):1197-1204. PubMed ID: 28500806
[TBL] [Abstract][Full Text] [Related]
43. Humoral immune responses against Plasmodium vivax MSP1 in humans living in a malaria endemic area in Flores, Indonesia.
Ak M; Jones TR; Charoenvit Y; Kumar S; Kaslow DC; Maris D; Marwoto H; Masbar S; Hoffman SL
Southeast Asian J Trop Med Public Health; 1998 Dec; 29(4):685-91. PubMed ID: 10772546
[TBL] [Abstract][Full Text] [Related]
44. IgG isotype to C-terminal 19 kDa of Plasmodium vivax merozoite surface protein 1 among subjects with different levels of exposure to malaria in Brazil.
Morais CG; Soares IS; Carvalho LH; Fontes CJ; Krettli AU; Braga EM
Parasitol Res; 2005 Apr; 95(6):420-6. PubMed ID: 15759156
[TBL] [Abstract][Full Text] [Related]
45. Humoral responses against the C-terminal region of merozoite surface protein 1 can be remembered for more than 30 years in persons exposed to Plasmodium vivax.
Lim KJ; Park JW; Yeom JS; Lee YH; Yoo SB; Oh JH; Sohn MJ; Bahk YY; Kim YS
Parasitol Res; 2004 Mar; 92(5):384-9. PubMed ID: 14745545
[TBL] [Abstract][Full Text] [Related]
46. Allele-specific antibodies to Plasmodium vivax merozoite surface protein-1: prevalence and inverse relationship to haemoglobin levels during infection.
Sepúlveda N; Morais CG; Mourão LC; Freire MF; Fontes CJ; Lacerda MV; Drakeley CJ; Braga ÉM
Malar J; 2016 Nov; 15(1):559. PubMed ID: 27852258
[TBL] [Abstract][Full Text] [Related]
47. Antibody response dynamics to the Plasmodium falciparum conserved vaccine candidate antigen, merozoite surface protein-1 C-terminal 19kD (MSP1-19kD), in Peruvians exposed to hypoendemic malaria transmission.
Torres KJ; Clark EH; Hernandez JN; Soto-Cornejo KE; Gamboa D; Branch OH
Malar J; 2008 Sep; 7():173. PubMed ID: 18782451
[TBL] [Abstract][Full Text] [Related]
48. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.
Soe S; Theisen M; Roussilhon C; Aye KS; Druilhe P
Infect Immun; 2004 Jan; 72(1):247-52. PubMed ID: 14688102
[TBL] [Abstract][Full Text] [Related]
49. Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission.
Zakeri S; Babaeekhou L; Mehrizi AA; Abbasi M; Djadid ND
Am J Trop Med Hyg; 2011 Jun; 84(6):944-50. PubMed ID: 21633032
[TBL] [Abstract][Full Text] [Related]
50. Sparse serological evidence of Plasmodium vivax transmission in the Ouest and Sud-Est departments of Haiti.
Weppelmann TA; von Fricken ME; Lam B; Telisma T; Existe A; Lemoine JF; Larkin J; Okech BA
Acta Trop; 2016 Oct; 162():27-34. PubMed ID: 27230796
[TBL] [Abstract][Full Text] [Related]
51. Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children.
Cole-Tobian JL; Michon P; Biasor M; Richards JS; Beeson JG; Mueller I; King CL
Infect Immun; 2009 Sep; 77(9):4009-17. PubMed ID: 19564376
[TBL] [Abstract][Full Text] [Related]
52. Comparison of naturally acquired antibody responses against the C-terminal processing products of Plasmodium vivax Merozoite Surface Protein-1 under low transmission and unstable malaria conditions in Sri Lanka.
Wickramarachchi T; Illeperuma RJ; Perera L; Bandara S; Holm I; Longacre S; Handunnetti SM; Udagama-Randeniya PV
Int J Parasitol; 2007 Feb; 37(2):199-208. PubMed ID: 17055511
[TBL] [Abstract][Full Text] [Related]
53. Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC).
Maestre A; Muskus C; Duque V; Agudelo O; Liu P; Takagi A; Ntumngia FB; Adams JH; Sim KL; Hoffman SL; Corradin G; Velez ID; Wang R
PLoS One; 2010 Jul; 5(7):e11437. PubMed ID: 20664684
[TBL] [Abstract][Full Text] [Related]
54. Adverse pregnancy outcomes are associated with Plasmodium vivax malaria in a prospective cohort of women from the Brazilian Amazon.
Dombrowski JG; Barateiro A; Peixoto EPM; Barros ABCDS; Souza RM; Clark TG; Campino S; Wrenger C; Wunderlich G; Palmisano G; Epiphanio S; Gonçalves LA; Marinho CRF
PLoS Negl Trop Dis; 2021 Apr; 15(4):e0009390. PubMed ID: 33914739
[TBL] [Abstract][Full Text] [Related]
55. Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children.
Stanisic DI; Javati S; Kiniboro B; Lin E; Jiang J; Singh B; Meyer EV; Siba P; Koepfli C; Felger I; Galinski MR; Mueller I
PLoS Negl Trop Dis; 2013 Nov; 7(11):e2498. PubMed ID: 24244763
[TBL] [Abstract][Full Text] [Related]
56. The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.
Courtin D; Oesterholt M; Huismans H; Kusi K; Milet J; Badaut C; Gaye O; Roeffen W; Remarque EJ; Sauerwein R; Garcia A; Luty AJ
PLoS One; 2009 Oct; 4(10):e7590. PubMed ID: 19859562
[TBL] [Abstract][Full Text] [Related]
57. The acquisition of long-lived memory B cell responses to merozoite surface protein-8 in individuals with Plasmodium vivax infection.
Kochayoo P; Kittisenachai N; Changrob S; Wangriatisak K; Muh F; Chootong P; Han ET
Malar J; 2019 May; 18(1):188. PubMed ID: 31151441
[TBL] [Abstract][Full Text] [Related]
58. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
Amoani B; Gyan B; Sakyi SA; Abu EK; Nuvor SV; Barnes P; Sarkodie-Addo T; Ahenkorah B; Sewor C; Dwomoh D; Theisen M; Cappello M; Wilson MD; Adu B
BMC Infect Dis; 2021 Apr; 21(1):332. PubMed ID: 33832450
[TBL] [Abstract][Full Text] [Related]
59. Acquisition of antibodies to merozoite surface protein 3 among residents of Korogwe, north eastern Tanzania.
Segeja MD; Mmbando BP; Seth MD; Lusingu JP; Lemnge MM
BMC Infect Dis; 2010 Mar; 10():55. PubMed ID: 20205959
[TBL] [Abstract][Full Text] [Related]
60. Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1.
Tentokam BCN; Amaratunga C; Alani NAH; MacDonald NJ; Narum DL; Salinas ND; Kwan JL; Suon S; Sreng S; Pereira DB; Tolia NH; Fujiwara RT; Bueno LL; Duffy PE; Coelho CH
Front Immunol; 2019; 10():2295. PubMed ID: 31636633
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
